Glaxo (GSK) Beats Earnings Estimates in Q3, Revenues Miss

GlaxoSmithKline plc GSK, one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Glaxo has created a joint venture (“JV”) with Pfizer earlier in 2019, thereby combining their consumer healthcare unit.

Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on its core assets and divesting non-core assets.

Meanwhile, like many of its peers, Glaxo is facing challenges in the form of COVID-19 restrictions, stiff competition, genericization and pricing pressure. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.

Glaxo’s performance has been mixed so far, with the company’s earnings beating expectations in two of the trailing four quarters, while missing the same twice. Overall, the company has delivered an average positive surprise of 7.33%.

Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings Beat: Glaxo reported core earnings of 93 cents per American depositary share in the third quarter of 2020, which beat our consensus estimate of 78 cents. Core earnings were up 1% year over year at constant exchange rate (“CER”).

Revenues Beat: Revenues were down 3% year over year at CER to $11.18 billion (£8.6 billion).  Revenues also missed the Zacks Consensus Estimate of $11.27 billion.

Key Stats: Sales in Vaccines segment declined 9% at CER while Consumer Healthcare sales increased 2%. Pharmaceuticals sales were also down 3% at CER. The Respiratory segment increased 26% at CER. HIV product sales were flat at CER. Shingrix sales declined 25% at CER due to lower adult wellness visits and vaccination rates in the United States.

2020 Guidance: Based on its current assessment of COVID-19 impact, Glaxo maintained its previous guidance for adjusted EPS to decline 1% to 4% at CER, year over year, in 2020.

Share Price Impact: Shares were down 0.3% in pre-market trading.

Check back later for our full write up on GSK earnings report later!

Zacks’ 2020 Election Stock Report: In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins. Check out the 2020 Election Stock Report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.